We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly (LLY) Mirikizumab Meets Ulcerative Colitis Study Goal
Read MoreHide Full Article
Eli Lilly and Company (LLY - Free Report) announced that its IL23 inhibitor, mirikizumab, met the primary and all key secondary endpoints in a phase III LUCENT-1 study in patients with moderate to severe ulcerative colitis (UC) who had failed conventional and/or biologic treatments.
UC is a chronic disease caused by inflammation of the colon that can lead to abdominal pain, frequent and urgent trips to the bathroom, bloody stools and incontinence.
In the study, mirikizumab met the primary endpoint of clinical remission, by controlling/resolving the inflammation of the colon at Week 12 versus placebo. Mirikizumab also achieved all key secondary endpoints compared to placebo at Week 12 by reducing bowel urgency, clinical response, endoscopic remission, symptomatic remission by high statistical significance. In fact, LUCENT-1 is the first and only phase III study of an IL23 inhibitor to result in reduced bowel urgency in UC patients.
Lilly’s shares have risen 13.0% this year so far against the industry’s decline of 0.5%.
Meanwhile, another study on mirikizumab, the LUCENT-2 maintenance study in patients who have completed the 12-week LUCENT-1 induction study, is also ongoing. Full data from LUCENT-1 as well as data from LUCENT-2 and LUCENT-3 (open label extension study) studies are expected to be presented at a future medical conference.
Mirikizumab is already being evaluated in phase III studies in other immune diseases like psoriasis and Crohn’s disease.
Two marketed IL23 inhibitors are J&J’s (JNJ - Free Report) Tremfya and AbbVie’s (ABBV - Free Report) Skyrizi (risankizumab). However, both the drugs are approved to treat plaque psoriasis. Skyrizi is in mid-stage development for UC.
Moderna’s earnings per share estimates have moved up from $12.72 to $27.72 per share for 2021 and from $11.45 to $14.96 for 2022 in the past 30 days. The stock has risen 49.4% so far this year.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Image: Bigstock
Lilly (LLY) Mirikizumab Meets Ulcerative Colitis Study Goal
Eli Lilly and Company (LLY - Free Report) announced that its IL23 inhibitor, mirikizumab, met the primary and all key secondary endpoints in a phase III LUCENT-1 study in patients with moderate to severe ulcerative colitis (UC) who had failed conventional and/or biologic treatments.
UC is a chronic disease caused by inflammation of the colon that can lead to abdominal pain, frequent and urgent trips to the bathroom, bloody stools and incontinence.
In the study, mirikizumab met the primary endpoint of clinical remission, by controlling/resolving the inflammation of the colon at Week 12 versus placebo. Mirikizumab also achieved all key secondary endpoints compared to placebo at Week 12 by reducing bowel urgency, clinical response, endoscopic remission, symptomatic remission by high statistical significance. In fact, LUCENT-1 is the first and only phase III study of an IL23 inhibitor to result in reduced bowel urgency in UC patients.
Lilly’s shares have risen 13.0% this year so far against the industry’s decline of 0.5%.
Meanwhile, another study on mirikizumab, the LUCENT-2 maintenance study in patients who have completed the 12-week LUCENT-1 induction study, is also ongoing. Full data from LUCENT-1 as well as data from LUCENT-2 and LUCENT-3 (open label extension study) studies are expected to be presented at a future medical conference.
Mirikizumab is already being evaluated in phase III studies in other immune diseases like psoriasis and Crohn’s disease.
Two marketed IL23 inhibitors are J&J’s (JNJ - Free Report) Tremfya and AbbVie’s (ABBV - Free Report) Skyrizi (risankizumab). However, both the drugs are approved to treat plaque psoriasis. Skyrizi is in mid-stage development for UC.
Lilly currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. A better-ranked biotech stock is Moderna (MRNA - Free Report) with a Zacks Rank #2 (Buy).
Moderna’s earnings per share estimates have moved up from $12.72 to $27.72 per share for 2021 and from $11.45 to $14.96 for 2022 in the past 30 days. The stock has risen 49.4% so far this year.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>